Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1a - Biogen

Drug Profile

Interferon beta-1a - Biogen

Alternative Names: Avonex; Avonex Pen; IFN-b-1a; Interferon β-1a

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Eisai Co Ltd; Merck & Co; Nektar Therapeutics
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 26 Mar 2018 Phase-II clinical trials in Multiple sclerosis (Combination therapy) in Germany (SC) (NCT03387046)
  • 29 Dec 2017 Merck KGaA plans the INCREASE phase II trial for Multiple Sclerosis in Germany in January 2018 , (NCT03387046)
  • 23 Oct 2017 Eisai and Biogen agree to co-promote Interferon beta-1a in Japan, India and other Asia-Pacific countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top